Lucid Diagnostics INC 10-Q quarterly reports

Lucid Diagnostics Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting increased revenue but also substantial net losses and significant cash burn, leading to a going concern warning.

Lucid Diagnostics reports increased revenue in Q1 2026, but net loss widens due to higher operating expenses and changes in convertible note valuation.

Lucid Diagnostics reports a slight revenue increase and significantly boosted cash reserves from recent offerings, but continues to face substantial doubt about its ability to continue as a going concern.

Lucid Diagnostics Inc. reported a significantly increased net loss for the first half of 2025, despite a stronger cash position from recent capital raises and progress in commercializing its EsoGuard test.

Lucid Diagnostics reports a net loss of $26.9 million for Q1 2025, while focusing on securing Medicare coverage for its EsoGuard test and highlighting a recent NCCN guidelines update.

Lucid Diagnostics saw revenue increase in Q3 2024 compared to the same period last year, but also experienced a net loss due to higher operating expenses and debt-related costs.

Lucid Diagnostics saw a significant increase in revenue in the second quarter of 2024, but ongoing losses and cash burn raise concerns about its ability to continue as a going concern.

Lucid Diagnostics saw a revenue increase in Q1 2024 compared to the same period last year, but continues to experience significant net losses.